Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02712320 · ClinicalTrials.gov registry record · Phase 3
Open-Label Safety Extension Study in Patients Who Have Previously Participated and Have Benefited From LMIS 50 mg
A Phase 3 study, sponsored by Foresee Pharmaceuticals Co..
- Completed
- Registry status
- Phase 3
- Development phase
- 30
- Enrollment target
NCT02712320 is a Phase 3 study that has completed, run by Foresee Pharmaceuticals Co.. The registered enrollment target is 30 participants.
The verdict
NCT02712320, a Phase 3 study, has completed, sponsored by Foresee Pharmaceuticals Co..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a safety extension of up to 12 months of additional treatment with LMIS 50 mg after the subject has completed 12 months of treatment under Protocol FP01C-13-001 and remain eligible for continued treatment with androgen deprivation therapy. Subjects participating in Protocol FP01C-13-001-EX will be followed for safety only.
Interventions
- DRUG LMIS 50 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2016-02 |
| Est. Completion | 2017-12-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02712320
The ClinicalTrials.gov registry entry for NCT02712320 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Foresee Pharmaceuticals Co., which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LMIS 50 mg is the first listed.
NCT02712320 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02712320 about?
NCT02712320 is a clinical study titled "Open-Label Safety Extension Study in Patients Who Have Previously Participated and Have Benefited From LMIS 50 mg". This is a safety extension of up to 12 months of additional treatment with LMIS 50 mg after the subject has completed 12 months of treatment under Protocol FP01C-13-001 and remain eligible for continued treatment with androgen deprivation therapy. Subjects participating in Protocol FP01C-13-001-EX w...
What is the current status of trial NCT02712320?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2016-02. Estimated completion is 2017-12-19.
What interventions are being tested in trial NCT02712320?
The interventions under investigation include: LMIS 50 mg (DRUG).
Who is sponsoring clinical trial NCT02712320?
This trial is sponsored by Foresee Pharmaceuticals Co., which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.